AD Pipeline Update: Eli Lilly Resubmits BLA for Lebrikizumab in AD
Eli Lilly has resubmitted its Biologics License Application (BLA) for Lebrikizumab for the treatment of moderate to severe atopic dermatitis (AD), with regulatory action anticipated in the second half of 2024. The Company announced the news along with its financial results for the first quarter of 2024 during a live webcast. Lebrikizumab is subcutaneous recombinant humanized IgG4 […]